Implementation bottlenecks of real time medication monitoring (evriMED) for improving adherence to anti-TB drugs among people with tuberculosis in Kilimanjaro, Tanzania

IF 1.9 Q3 INFECTIOUS DISEASES
Rehema Anenmose Maro , Alan Mtenga , Benson Mtesha , Krisanta Wilhelm , Naomi Lekashingo , Marion Sumari-de Boer , Kennedy Ngowi
{"title":"Implementation bottlenecks of real time medication monitoring (evriMED) for improving adherence to anti-TB drugs among people with tuberculosis in Kilimanjaro, Tanzania","authors":"Rehema Anenmose Maro ,&nbsp;Alan Mtenga ,&nbsp;Benson Mtesha ,&nbsp;Krisanta Wilhelm ,&nbsp;Naomi Lekashingo ,&nbsp;Marion Sumari-de Boer ,&nbsp;Kennedy Ngowi","doi":"10.1016/j.jctube.2023.100409","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Digital Adherence Tools (DATs), which include real-time medication monitoring and Short Message Service (SMS) reminders, have been reported to improve medication adherence among people with Tuberculosis (TB). Recently, in limited resource settings, DATs have been described as a promising tool to monitor patients’ medication behaviour. We aimed to determine implementation bottlenecks of real-time medication monitoring using the evriMED device.</p></div><div><h3>Method</h3><p>We conducted a research study using a mixed-methods approach, involving both people with TB s and directly observed treatment (DOT) providers who participated in the REMIND-TB trial and utilized the evriMED devices. EvriMED is a medication dispenser with internet connectivity that can send real-time SMS reminders. To gather data, we extracted reports from the Wisepill dashboard, specifically the client status report. This report documented the activity status of all devices, including communication and battery status. Additionally, we conducted in-depth interviews with people with TB and TB care providers who were involved in implementing the Remind TB trial in the Kilimanjaro region. These interviews were guided by the MIDI (Measurement Instrument for Determinants of Innovation), which helps identify the factors influencing the implementation of innovations such as evriMED.</p></div><div><h3>Results</h3><p>Out of the initial 281 participants who were given devices, 245 completed the 6-month follow-up period. The findings indicate that at month 6, most of the devices (49%) reported battery-related challenges. Additionally, forty devices (14%) had reported more than one incidence of losing communication. Through interviews with participants, we observed that evriMED was perceived as user-friendly, and the people with TB reported high satisfaction as the device facilitated improved medication intake. TB care providers also said that evriMED was a relevant tool to be used by the people with TB. However, during the in-depth interview certain implementation bottlenecks were identified, including network issues, limited training, and low technology knowledge among TB care providers, who found the procedure of using the evriMED to be time-consuming.</p></div><div><h3>Conclusion</h3><p>Implementation of evriMED was perceived as user-friendly and highly satisfactory by people with TB. Certain implementation bottlenecks were identified as potential barriers to the use of devices. These bottlenecks include network issues, limited training, battery-related challenges and low technological knowledge among TB care providers, which may have contributed to communication loss. Further research may be needed to address these limitations and develop effective strategies to facilitate the successful implementation of evriMED as a tool for improving medication intake among people with TB.</p></div>","PeriodicalId":37942,"journal":{"name":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","volume":"34 ","pages":"Article 100409"},"PeriodicalIF":1.9000,"publicationDate":"2023-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2405579423000657/pdfft?md5=8a6e58513649b2811484d3d610aee588&pid=1-s2.0-S2405579423000657-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405579423000657","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Digital Adherence Tools (DATs), which include real-time medication monitoring and Short Message Service (SMS) reminders, have been reported to improve medication adherence among people with Tuberculosis (TB). Recently, in limited resource settings, DATs have been described as a promising tool to monitor patients’ medication behaviour. We aimed to determine implementation bottlenecks of real-time medication monitoring using the evriMED device.

Method

We conducted a research study using a mixed-methods approach, involving both people with TB s and directly observed treatment (DOT) providers who participated in the REMIND-TB trial and utilized the evriMED devices. EvriMED is a medication dispenser with internet connectivity that can send real-time SMS reminders. To gather data, we extracted reports from the Wisepill dashboard, specifically the client status report. This report documented the activity status of all devices, including communication and battery status. Additionally, we conducted in-depth interviews with people with TB and TB care providers who were involved in implementing the Remind TB trial in the Kilimanjaro region. These interviews were guided by the MIDI (Measurement Instrument for Determinants of Innovation), which helps identify the factors influencing the implementation of innovations such as evriMED.

Results

Out of the initial 281 participants who were given devices, 245 completed the 6-month follow-up period. The findings indicate that at month 6, most of the devices (49%) reported battery-related challenges. Additionally, forty devices (14%) had reported more than one incidence of losing communication. Through interviews with participants, we observed that evriMED was perceived as user-friendly, and the people with TB reported high satisfaction as the device facilitated improved medication intake. TB care providers also said that evriMED was a relevant tool to be used by the people with TB. However, during the in-depth interview certain implementation bottlenecks were identified, including network issues, limited training, and low technology knowledge among TB care providers, who found the procedure of using the evriMED to be time-consuming.

Conclusion

Implementation of evriMED was perceived as user-friendly and highly satisfactory by people with TB. Certain implementation bottlenecks were identified as potential barriers to the use of devices. These bottlenecks include network issues, limited training, battery-related challenges and low technological knowledge among TB care providers, which may have contributed to communication loss. Further research may be needed to address these limitations and develop effective strategies to facilitate the successful implementation of evriMED as a tool for improving medication intake among people with TB.

在坦桑尼亚乞力马扎罗山改善结核病患者抗结核药物依从性的实时药物监测(evriMED)的实施瓶颈
导言据报道,包括实时用药监测和短信服务(SMS)提醒在内的数字依从性工具(DATs)可改善肺结核(TB)患者的用药依从性。最近,在资源有限的环境中,DATs 被描述为监测患者用药行为的一种很有前途的工具。我们采用混合方法开展了一项研究,参加 REMIND-TB 试验并使用 evriMED 设备的结核病患者和直接观察治疗(DOT)提供者都参与了这项研究。evriMED 是一种可连接互联网的配药器,可发送实时短信提醒。为了收集数据,我们从 Wisepill 面板中提取了报告,特别是客户状态报告。该报告记录了所有设备的活动状态,包括通信和电池状态。此外,我们还对参与在乞力马扎罗山地区实施 Remind TB 试验的肺结核患者和肺结核护理提供者进行了深入访谈。这些访谈以 MIDI(创新决定因素测量工具)为指导,该工具有助于确定影响 evriMED 等创新实施的因素。结果表明,在第 6 个月时,大多数设备(49%)报告了与电池有关的问题。此外,有 40 台设备(14%)报告了不止一次失去通信的情况。通过对参与者的访谈,我们发现 evriMED 被视为用户友好型设备,结核病患者对该设备的满意度很高,因为该设备有助于改善药物摄入。结核病护理人员也表示 evriMED 是结核病患者可以使用的相关工具。然而,在深入访谈中也发现了一些实施瓶颈,包括网络问题、培训有限、结核病护理人员的技术知识不足,他们认为使用 evriMED 的程序非常耗时。某些实施瓶颈被认为是使用设备的潜在障碍。这些瓶颈包括网络问题、有限的培训、与电池有关的挑战以及结核病护理提供者的技术知识水平较低,这可能是造成通信中断的原因。可能需要进一步研究来解决这些限制因素,并制定有效的策略来促进 evriMED 的成功实施,使其成为改善肺结核患者药物摄入的工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases Medicine-Pulmonary and Respiratory Medicine
CiteScore
4.00
自引率
5.00%
发文量
44
审稿时长
30 weeks
期刊介绍: Journal of Clinical Tuberculosis and Mycobacterial Diseases aims to provide a forum for clinically relevant articles on all aspects of tuberculosis and other mycobacterial infections, including (but not limited to) epidemiology, clinical investigation, transmission, diagnosis, treatment, drug-resistance and public policy, and encourages the submission of clinical studies, thematic reviews and case reports. Journal of Clinical Tuberculosis and Mycobacterial Diseases is an Open Access publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信